Clinical trials: Tamsulosin
Benign Prostatic Hyperplasia (BPH)
PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination
To compare the relative bioavailability and pharmacokinetic characteristics of a newly single pill combination of finasteride and tamsulosin with a conventional combination of finasteride and tamsulosin in healthy subjects with a…
- Trial name
- NCT01829893
- Testing
- In combination of 0.2mg finasteride and 5mg tamsulosin, GL2701 capsule
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
EC905, Pharmacokinetics
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
A study to assess the amount of drug in the blood of young to middle aged, healthy, male subjects after they received the final formulation of EC905 compared to solifenacin (Vesicare®) and tamsulosin OCAS (Omnic OCAS®).
- Conditions
- EC905, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT01953887
- Testing
- EC905, solifenacin, tamsulosin
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Hyperplasia
Bioequivalence - Duodart Against Avodart & Omnic
Open-label, randomized, single dose, two-treatment, two-way crossover study
- Trial name
- NCT01657851
- Testing
- dutasteride/tamsulosin, dutasteride, tamsulosin
- Where
- Russia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healty Male Volunteers
CKD-397 Drug-drug Interaction Study (B)
The purpose of this study is to investigate to effect of tadalafil on the pharmacokinetic properies of tamsulosin
- Trial name
- CKD-397DDI(B) (NCT02247505)
- Testing
- Harnal-D Cap. 0.2mg, Cialis Tab. 5mg
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Prostatic Hyperplasia
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
The primary objective of this study is to determine the bioavailability of a FDC capsule formulation of dutasteride and tamsulosin hydrochloride (0.5 milligram [mg]/0.2 mg) relative to coadministration of one dutasteride 0.5 mg…
- Trial name
- NCT02509104
- Testing
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Pharmacokinetics of Tamsulosin Hydrochloride
A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects
The purpose of this study is to investigate the relative bioavailability of two types of prolonged release formulation of tamsulosin hydrochloride in Chinese healthy subjects. The safety of tamsulosin formulation is also compared.
- Trial name
- NCT02138773
- Testing
- Tamsulosin formulation-A, Tamsulosin formulation-B
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma China, Inc.
EC905, Pharmacokinetics
A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)
Tamsulosin (sold under the name Omnic OCAS) is used for treatment of voiding complaints related to an enlarged prostate. Solifenacin (sold under the name Vesicare) is used for the treatment of patients suffering from problems…
- Conditions
- EC905, Pharmacokinetics, Multiple Dose, Healthy Subjects
- Trial name
- NCT01953848
- Testing
- EC905
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Hyperplasia
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
This study will be an open-label, randomized, single dose, two-period crossover study to determine the bioavailability of a fixed dose combination capsule formulation of dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg)…
- Trial name
- ARI114694 (NCT01254071)
- Testing
- Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
- Where
- Australia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ureteric Stone
The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms
To estimate the efficacy of tamsulosin in: A - Expulsion of lower ureteric stones from10-15 mm diameters (primary goal). B - Pain relief and hyronephrosis improvement (secondary goal).
- Trial name
- NCT03274700
- Testing
- Tamsulosin.
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Prostatic Hyperplasia
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia
This study is an open-label, randomized, single dose, multi-stage, cross-over study in healthy male subjects of North East Asian ancestry.
- Trial name
- NCT01495026
- Testing
- Dutasteride (0.5mg, fasted state), Dutasteride (0.5mg, fed state), Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bioequivalance
Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x4, replicated, two treatments, four periods, two sequences controlled clinical study
- Trial name
- ACL25-PC006 (NCT07698275)
- Testing
- TAMSULOSIN TEST, OMNIC OCAS REFERENCE
- Where
- Mexico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ADIUM
Benign Prostatic Hyperplasia
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers
This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc.
- Trial name
- NCT03887858
- Testing
- Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Adult Males Volunteers
A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0,4 mg…
- Trial name
- NCT07146711
- Testing
- Tamsulosin (0.4 mg/j), Omnic Ocas®,
- Where
- Armenia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Berlin-Chemie AG Menarini Group
Prostatic Hyperplasia
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
This will be an open-label, three-period, fixed-sequence study to evaluate the drug-drug interaction, pharmacokinetics and safety of dutasteride and tamsulosin when administered alone and in-combination in Chinese healthy male…
- Trial name
- NCT01957189
- Testing
- Dutasteride and Tamsulosin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Pharmacokinetics
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the concentrations of tamsulosin HCl after combined dosing.
- Conditions
- Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)
- Trial name
- NCT02169713
- Testing
- Mirabegron, Solifenacin succinate, Tamsulosin HCl
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
The purpose of this study is to investigate and compare the pharmacokinetic characteristics and safety/tolerability between JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg)and co-administration of Solifenacin and Tamsulosin between…
- Conditions
- LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02494349
- Testing
- JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Postoperative Urinary Retention
Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
Double blinded, randomized controlled prospective study looking at 2 preoperative doses of Tamsulosin an alpha-adrenergic blocker in preventing post-operative urinary retention.
- Trial name
- NCT02958878
- Testing
- Tamsulosin
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Ascension Health
Healthy
Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
Study to investigate the effect of CYP3A4 inhibition by ketoconazole on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability
- Trial name
- NCT02264171
- Testing
- Tamsulosin HCl, Ketoconazole
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
BPH
Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study
Comparison between tamsulosin and Tadalafil in management of benign prostatic hyperplasia A Randomised Trial
- Trial name
- NCT05818670
- Testing
- Tamsulosin, Tadalafil
- Where
- 2 sites in Egypt
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Erectile Dysfunction, Benign Prostatic Hyperplasia
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
We investigate the potential pharmacokinetic drug-drug interaction between Tadalafil and Tamsulosin in healthy male volunteers who receive Tadalafil alone, Tamsulosin alone, and both together in a 3 period repeatedly.
- Trial name
- NCT02239484
- Testing
- Tadalafil, Tamsulosin, Tadalafil + Tamsulosin
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited